Want to see BNBX full AI Analyst Report?
Top Page
BNB Plus
(NASDAQ:BNBX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.34
▼(-76.96% Downside)
Action:Reiterated
Date:06/26/26
The score is primarily weighed down by weak financial performance—extreme losses and persistent cash burn despite a revenue rebound—combined with bearish technicals (below major moving averages and negative MACD). Valuation provides limited support because earnings are negative and no dividend yield is available, while the recent financing event modestly helps liquidity but carries potential dilution and seniority risk for common stock.
Positive Factors
Low leverage and stronger equity base
Very low debt and a marked increase in equity provide durable financial flexibility over the next several months. This reduces bankruptcy and rollover risk, supports continuing operations while management pursues strategic options, and improves the company's ability to access financing without immediate distress.
Negative Factors
Extreme operating and net losses
Margins are structurally weak: very low gross margin and extreme negative operating/net margins show costs far exceed revenue. Without meaningful structural cost reduction or sustained higher revenue, these losses will persist, undermining long-term value creation and financing capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger equity base
Very low debt and a marked increase in equity provide durable financial flexibility over the next several months. This reduces bankruptcy and rollover risk, supports continuing operations while management pursues strategic options, and improves the company's ability to access financing without immediate distress.
Read all positive factors
BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.51M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)2.32
Revenue Growth-44.78%
EPS Growth92.56%
CountryUS
Employees26
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-39.93
Shares Outstanding7,197,228
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit-0.35
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-82.5
Revenue Forecast (FY)$7.40M
BNB Plus Business Overview & Revenue Model
Company Description
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)....
BNB Plus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 2.14M | 3.43M | 13.37M | 18.17M | 9.03M |
| Gross Profit | 910.30K | 838.91K | 1.02M | 5.53M | 5.05M | 4.93M |
| EBITDA | -34.70M | -15.26M | -13.33M | -9.59M | -12.68M | -11.68M |
| Net Income | -34.48M | -15.16M | -6.99M | -9.95M | -8.38M | -16.03M |
Balance Sheet | ||||||
| Total Assets | 13.63M | 4.44M | 12.79M | 13.65M | 22.27M | 14.42M |
| Cash, Cash Equivalents and Short-Term Investments | 949.09K | 1.67M | 6.43M | 7.15M | 15.22M | 6.55M |
| Total Debt | 0.00 | 193.25K | 739.16K | 1.24M | 0.00 | 0.00 |
| Total Liabilities | 1.50M | 2.50M | 3.82M | 8.78M | 9.36M | 3.30M |
| Stockholders Equity | 12.51M | 2.30M | 9.14M | 4.95M | 12.91M | 11.11M |
Cash Flow | ||||||
| Free Cash Flow | -13.80M | -12.83M | -14.12M | -6.30M | -9.47M | -15.94M |
| Operating Cash Flow | -13.79M | -12.52M | -13.71M | -6.22M | -8.98M | -13.39M |
| Investing Cash Flow | -2.96M | -292.12K | -407.90K | -1.10M | -489.55K | -2.55M |
| Financing Cash Flow | 9.96M | 8.05M | 13.40M | 0.00 | 18.13M | 14.70M |
BNB Plus Technical Analysis
Negative
1.48
Price Trends
0.45
Negative
0.57
Negative
1.64
Negative
Market Momentum
-0.03
Positive
36.25
Neutral
27.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.45, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 27.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.
BNB Plus Risk Analysis
BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BNB Plus Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
45 Neutral | $2.51M | >-0.01 | -259.18% | ― | -44.78% | 92.56% | |
44 Neutral | $6.05M | -0.58 | -537.60% | ― | ― | 98.32% | |
43 Neutral | $3.49M | >-0.01 | -496.37% | ― | -87.25% | 87.10% | |
42 Neutral | $5.19M | -0.17 | -174.16% | ― | 33.26% | 49.65% |
* Financial Sector Average
BNBX
BNB Plus
0.35
-4.77
-93.20%
NDRA
ENDRA Life Sciences
4.76
-4.08
-46.15%
INBS
Intelligent Bio Solutions
2.17
-16.03
-88.08%
ISPC
iSpecimen
2.29
-39.31
-94.50%
BGLC
BioNexus Gene Lab Corp
1.93
-3.89
-66.84%
BNB Plus Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BNB Plus Amends Registration Rights Agreement Timeline
Neutral
Jul 2, 2026
On June 29, 2026, BNB Plus entered into an amendment, effective June 23, 2026, to its May 26, 2026 Registration Rights Agreement with purchasers holding at least 50.1% of its registrable securities. The amendment extends the filing date for regist...
Business Operations and StrategyPrivate Placements and Financing
BNB Plus Announces New Preferred Stock Financing Plans
Positive
May 27, 2026
On May 26, 2026, BNB Plus Corp. signed agreements for a private placement and warrant inducement transaction to raise up to $5 million via two new series of convertible preferred stock, Series B-1 and Series B-2, structured to be senior to common ...
Shareholder MeetingsStock Split
BNB Plus Shareholders Approve Board Reverse Split Authority
Neutral
Apr 29, 2026
On April 28, 2026, BNB Plus Corp. held a special meeting of stockholders at which investors approved granting the board of directors 12-month discretionary authority to implement a reverse stock split at a ratio between one-for-five and one-for-th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.